APO-TIAPROFENIC TABLETS -300MG 300 MG
TIAPROFENIC ACID : 300 MG · DIN 02136120 · APOTEX INC
Health Canada status: CANCELLED POST MARKET
What is APO-TIAPROFENIC TABLETS -300MG?
APO-TIAPROFENIC TABLETS -300MG 300 MG contains TIAPROFENIC ACID : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02136120, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 17-Apr-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02136120 |
|---|---|
| Brand name | APO-TIAPROFENIC TABLETS -300MG |
| Generic / active ingredient | TIAPROFENIC ACID : 300 MG |
| Manufacturer | APOTEX INC |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AE11 TIAPROFENIC ACID |
| AHFS class | 12:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 17-Apr-2025 |
| Original market date | 1994-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M01AE11 TIAPROFENIC ACID. 2 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TEVA-TIAPROFENIC ACID | 200 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02179679 |
| TEVA-TIAPROFENIC ACID | 300 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02179687 |
| ALBERT TIAFEN SR | 300 MG | CAPSULE (SUSTAINED-RELEASE) | AVENTIS PHARMA INC | CANCELLED PRE MARKET | DIN 02152576 |
| ALBERT TIAFEN TAB 200MG | 200 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 01924613 |
| ALBERT TIAFEN TAB 300MG | 300 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 01924621 |
| APO-TIAPROFENIC TABLETS-200MG | 200 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 02136112 |
| DOM-TIAPROFENIC | 200 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02231059 |
| DOM-TIAPROFENIC | 300 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02231060 |
| NU-TIAPROFENIC - TAB 200MG | 200 MG | TABLET | NU-PHARM INC | CANCELLED POST MARKET | DIN 02146878 |
| NU-TIAPROFENIC - TAB 300MG | 300 MG | TABLET | NU-PHARM INC | CANCELLED POST MARKET | DIN 02146886 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.